SEC Comment Letter 0000000000-24-008324 to REVELATION BIOSCIENCES, INC. (REVB)
REVELATION BIOSCIENCES, INC.
Date: July 23, 2024 · CIK: 0001810560 · Accession: 0000000000-24-008324
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280908
Letter
July 23, 2024 James Rolke Chief Executive Officer Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 Re:Revelation Biosciences, Inc. Registration Statement on Form S-3 Filed July 19, 2024 File No. 333-280908 Dear James Rolke: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Joseph P. Galda
Show Raw Text
July 23, 2024
James Rolke
Chief Executive Officer
Revelation Biosciences, Inc.
4660 La Jolla Village Drive, Suite 100
San Diego, California 92122
Re:Revelation Biosciences, Inc.
Registration Statement on Form S-3
Filed July 19, 2024
File No. 333-280908
Dear James Rolke:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Joseph P. Galda